You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations.
Click “OK” to confirm you are a Healthcare Professional.
Met with Resolute Onyx DES (17.1%) noninferior to BioFreedom DCS (16.9%) for cardiac death (CD), myocardial infarction (MI), and stent thrombosis (ST)‡
Low event rates shown for Resolute Onyx DES in a highly complex HBR patient population, including significantly lower MI versus BioFreedom DCS.#
The first study in the United States and Japan evaluating 1-month DAPT duration in HBR patients with a current DES.
The Onyx ONE Clear study showed 7.0% cardiac death or myocardial infarction at one year, beating the performance goal of 9.7%.1
Third-party brands are trademarks of their respective owners.
Matching LEADERS FREE inclusion criteria.
At 1 year.
Device success was not a powered endpoint or adjusted for multiplicity.
Crossover was not prespecified, powered, or adjusted for multiplicity.
From 1 month to 1 year.
Post-hoc analyses were not powered.
Patients must be free of spontaneous MI, repeat revascularisation, stroke, stent thrombosis, and death through 1 month.
ZEUS, LEADERS FREE, and SENIOR trials.
Kirtane A, et al. One Month Dual Antiplatelet Therapy in High Bleeding Risk Patients: Primary Results of Onyx ONE Clear. Presented online at ACC 2020.
Windecker S, Latib A, Kedhi E, et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. N Engl J Med. March 26, 2020;382(13):1208-1218.
Kedhi E, Latib A, Abizaid A, et al. Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy. Am Heart J. August 2019;214:134-141.